Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Care topic
No spam. Unsubscribe anytime.
Advocates urge Vermont House Health Care Committee to adopt House Bill 302 to expand fertility coverage
Summary
On April 10 advocates, patients and providers told the House Health Care Committee that House Bill 302 would expand private and Medicaid coverage for fertility treatment, diagnostic care and medically necessary fertility preservation. Witnesses described financial, emotional and access barriers and asked lawmakers to take up the bill next year.
MONTPELIER, Vt. — Advocates, patients and medical providers told the Vermont House Health Care Committee on April 10 that House Bill 302 should be enacted to require private insurers and Medicaid to cover fertility treatment, diagnostic care and medically necessary fertility preservation.
Kate Weldon LeBlanc, executive director of All Paths Family Building, told the committee that the bill “is pro family and joyful legislation” and said advocates are asking lawmakers to take it up next year because the measure is not advancing this session. The bill’s lead sponsor is Representative Debash Bartley.
House Bill 302 would require private and public insurers in Vermont to cover fertility treatments, diagnostic services and medically necessary fertility preservation. Witnesses said the proposal aims to be inclusive of LGBTQIA families, to cover those who experience recurrent pregnancy loss as well as people who cannot conceive, and to allow medically indicated preimplantation genetic testing in appropriate circumstances, though the current draft does not require insurers to cover genetic screening.
Advocates and patients described the financial scale of fertility care and the effect on treatment decisions. “It’s typically around like $15,000 to $20,000 just to give you a ballpark of paying out of pocket,” Weldon LeBlanc said. Patient witnesses described using savings and credit cards, facing the prospect of medical debt, and foregoing some tests or treatments because of cost. One witness, Maggie Husband, described years of treatment and a life-threatening episode tied to reproductive care and said she has spent about $10,000 out of pocket so far.
Medical providers from Northeastern Reproductive Medicine in Colchester said Vermont has limited clinical capacity. Northeastern’s staff told the committee their clinic receives about 650 new patients a year and sees roughly 75 percent of people seeking fertility care in the state; University of Vermont’s program was described as smaller and carrying a wait list (committee testimony cited a 12‑month wait at UVM). Advocates said that coverage mandates in neighboring states spurred clinic expansion: after New Hampshire enacted a law in 2019 that took effect in 2020, Boston IVF expanded with a full-service clinic in Bedford, New Hampshire.
Witnesses described how different coverages interact. Several speakers said state employees have fertility benefits; UVM employees were described as having a limited benefit (witnesses said it is a $15,000 lifetime benefit paid at about 50 percent after deductible). Witnesses also said teachers and municipal employees may have different plans and therefore different levels of coverage.
Committee members asked about cost data and timelines. Weldon LeBlanc said advocates plan to review multi‑year claims and utilization data from states that enacted similar laws, particularly New Hampshire, to estimate Vermont’s fiscal impact. She also noted an economic argument advanced elsewhere: lawmakers in New Hampshire cited potential labor‑market and economic development benefits when that state enacted its law.
Several witnesses described nonfinancial barriers that affect uptake and outcomes, including waiting lists, limited clinic capacity and the emotional toll of infertility. Advocates emphasized that some people who need genetic testing for serious inherited conditions are left without coverage in many states, and that HB302’s language attempts to include medically necessary fertility preservation and some protections for those cases.
No formal vote or committee action on House Bill 302 occurred during the hearing. Witnesses asked committee members to remember the testimony next year and to take up the bill when it returns to committee.
The hearing also included brief discussion of a separate bill that some committee members said they were preparing (referred to in testimony as S.27), which addresses medical debt; a committee member noted fertility care can be a driver of medical debt for some patients.
